All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Aaron Reed's testosterone black box claims, fact-checked

Aaron Reed

Instagram creator

55.1K viewsView on Instagram→

Quick answer

The FDA's 2024 revision to testosterone labeling removed cardiovascular warning language added in 2015, reflecting updated evidence from the TRAVERSE trial (Lincoff et al., 2023, NEJM), which found no significant increase in major adverse cardiac events in hypogonadal men treated with testosterone. Appropriate TRT candidacy still requires confirmed low serum testosterone on two separate morning draws plus clinical symptoms, per Endocrine Society guidelines. Reed's suggestion that testosterone replacement could substitute for multiple medications in older men has no clinical support and should not be acted on without physician evaluation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @aaronw.reed actually say?

Aaron Reed is celebrating the FDA's removal of the black box warning from testosterone products, arguing this vindicates TRT and proves the hormone has been unfairly demonized. He frames it as a cultural win, compares testosterone to insulin, and suggests modern environmental exposures are systematically suppressing men's testosterone levels. He also claims older men relying on multiple medications would be better served by testosterone replacement alone.

He made several specific arguments worth unpacking: that testosterone is a bioidentical hormone with a long safety record, that everyday environmental factors are non-accidentally lowering testosterone, and that the COVID vaccine received a black box warning while testosterone lost one. He rounds out the video by dismissing skeptics of TRT as "stupid" and encouraging viewers to DM him about hormone therapy.

Does the science back this up?

Partially. The FDA did revise testosterone labeling in 2024, removing the cardiovascular warning that had been added in 2015. But the rest of Reed's claims range from oversimplified to outright misleading.

On the black box comparison: the mRNA COVID vaccines received a myocarditis warning for adolescent males, not a general black box, and that is a distinct regulatory category. Treating these as equivalent swaps is a rhetorical move, not a scientific one.

On environmental testosterone disruption: there is legitimate evidence that endocrine-disrupting chemicals, including phthalates and BPA, can lower testosterone. Travison et al. (2007, Journal of Clinical Endocrinology and Metabolism) documented a population-level decline in male testosterone over decades, and researchers have pointed to obesity, sedentary behavior, and environmental chemical exposure as probable contributors. Reed is not wrong that the modern environment is not neutral here. But his claim that "not one thing we do in our daily" accidentally raises testosterone ignores exercise, sleep, and dietary fat, all of which have documented effects on testosterone levels.

On replacing multiple medications with testosterone: this is the most dangerous overreach in the video. There is no clinical basis for the claim that testosterone can replace most medications in elderly men. This is not just unsupported, it is potentially harmful advice.

What did they get wrong (or right)?

Reed gets partial credit for the basics. Testosterone is a naturally occurring hormone. Symptomatic hypogonadism is underdiagnosed and undertreated. The 2015 cardiovascular warning was added following the TLANDO/Bhasin-era controversy and faced ongoing scientific dispute. Its removal reflects updated evidence, including the TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), which found testosterone replacement did not increase major cardiovascular events in men with hypogonadism and elevated cardiovascular risk.

But he gets several things wrong. Calling women on hormonal contraception "steroid users" in the same breath as TRT patients is technically defensible at a molecular level but contextually misleading. Synthetic progestins and ethinyl estradiol are not bioidentical and carry different receptor profiles than endogenous hormones. The comparison generates heat, not light.

His claim that "testosterone is not a steroid" followed immediately by admitting it is "technically a steroid hormone" is just confusing. He's probably trying to separate it from anabolic-androgenic steroid abuse, a fair distinction, but he muddies it.

The most irresponsible line in the video is suggesting older men should replace "90 pills" with testosterone. That is not how polypharmacy works, and no credentialed clinician would say otherwise.

What should you actually know?

The FDA labeling change is real and meaningful. The 2023 TRAVERSE trial was the largest randomized trial of testosterone in older men with hypogonadism to date, enrolling over 5,200 participants, and it did not find increased rates of major adverse cardiac events compared to placebo. That was the evidence basis for reconsidering the warning language.

What TRT is appropriate for: diagnosed hypogonadism, confirmed by two morning serum testosterone measurements below 300 ng/dL with accompanying symptoms, per Endocrine Society guidelines (Bhasin et al., 2018). It is not a general wellness intervention for men with low-normal levels.

Environmental endocrine disruption is a legitimate research area. Swan et al. (2021, Count Down) and multiple epidemiological studies have linked phthalate exposure to reduced testosterone. But the causal picture is complicated, and the leap from "chemicals exist" to "everything is by design" is conspiratorial, not scientific.

If you are considering TRT, the conversation starts with a lab panel and a physician, not a DM to an influencer. Testosterone therapy has real risks including erythrocytosis, sleep apnea exacerbation, infertility, and potential effects on lipid profiles that require monitoring.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Aaron Reed's testosterone black box claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Aaron Reed's testosterone black box claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Claim verdict

The useful answer behind this video

Claim being checked

The FDA's 2024 revision to testosterone labeling removed cardiovascular warning language added in 2015, reflecting updated evidence from the TRAVERSE trial (Lincoff et al.

FormBlends verdict

The FDA's 2024 revision to testosterone labeling removed cardiovascular warning language added in 2015, reflecting updated evidence from the TRAVERSE trial (Lincoff et al., 2023, NEJM), which found no significant increase in major adverse cardiac events in hypogonadal men treated with testosterone. Appropriate TRT candidacy still requires confirmed low serum testosterone on two separate morning draws plus clinical symptoms, per Endocrine Society guidelines. Reed's suggestion that testosterone replacement could substitute for multiple medications in older men has no clinical support and should not be acted on without physician evaluation.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The FDA's 2024 revision to testosterone labeling removed cardiovascular warning language added in 2015, reflecting updated evidence from the TRAVERSE trial (Lincoff et al., 2023, NEJM), which found no significant increase in major adverse cardiac events in hypogonadal men treated with testosterone. Appropriate TRT candidacy still requires confirmed low serum testosterone on two separate morning draws plus clinical symptoms, per Endocrine Society guidelines. Reed's suggestion that testosterone replacement could substitute for multiple medications in older men has no clinical support and should not be acted on without physician evaluation.
  • The TRAVERSE trial (Lincoff et al., 2023, NEJM), with 5,246 participants, found testosterone replacement did not significantly increase major adverse cardiovascular events in hypogonadal men with elevated CV risk, supporting the FDA labeling revision.
  • Endocrine Society guidelines define treatable hypogonadism as two morning serum testosterone readings below 300 ng/dL combined with clinical symptoms, not subjective feelings of low energy alone.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The TRAVERSE trial (Lincoff et al., 2023, NEJM), with 5,246 participants, found testosterone replacement did not significantly increase major adverse cardiovascular events in hypogonadal men with elevated CV risk, supporting the FDA labeling revision.
  • Endocrine Society guidelines define treatable hypogonadism as two morning serum testosterone readings below 300 ng/dL combined with clinical symptoms, not subjective feelings of low energy alone.
  • Travison et al. (2007, JCEM) documented a population-level decline in male testosterone over several decades, with obesity, sedentary lifestyle, and chemical exposure cited as likely contributors, not a single coordinated suppression.
  • Phthalates and BPA have documented associations with lower testosterone in epidemiological studies, but claims about radio frequencies and clothing lacking cited evidence remain speculative.
  • Testosterone therapy carries real monitoring requirements: hematocrit, PSA, lipid panels, and symptom tracking for sleep apnea and cardiovascular changes are standard of care.
  • The comparison between women on hormonal contraception and men on TRT is technically rooted in steroid hormone chemistry but collapses when you consider that synthetic progestins and ethinyl estradiol have distinct receptor profiles and risk categories.
  • No clinical guideline supports replacing multiple medications with testosterone in older men. This claim in the video is the most medically irresponsible and should be disregarded without consultation with a licensed physician.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Aaron Reed · Instagram creator

55.1K views on this video

Testosterone: Breaking Down Myths and Understanding Its True Value We discuss the recent removal of the black box warning from testosterone, challenging misconceptions about the hormone and highlight

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Aaron Reed, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.